Amgen's Kyprolis fails a Phase III test; Supernus gets on the FDA fast track;

@FierceBiotech: Merck wins FDA nod for a weaker form of its embattled sleep drug. Article | Follow @FierceBiotech

@DamianFierce: ICYMI yesterday: $MRK's suvorexant will sell as Belsomra, but dosing issue will likely limit its market value. Article | Follow @DamianFierce

@EmilyMFierce: Science! What's Up With That: Why It's So Hard to Catch Your Own Typos. Wired story | Follow @EmilyMFierce

> Amgen's ($AMGN) Kyprolis, acquired in its $10.4 billion deal for Onyx Pharmaceuticals, failed to meet its primary endpoint in a Phase III trial on advanced refractory multiple myeloma. Story (sub. req.)

> Supernus Pharmaceuticals ($SUPN) secured the FDA's fast-track designation for SPN-810, a Phase III-ready treatment for ADHD. More

> Biotech NewLink Genetics ($NLNK) told Reuters it has enough doses of its experiential Ebola vaccine to kick off a first human trial this summer. News

Pharma News

@FiercePharma: ICYMI: This week's issue of FiercePharmaMarketing. Want more? Subscribe here. | Follow @FiercePharma

@EricPFierce: ICYMI yesterday: Merck KGaA has to rely on AZ as its pharma sales contract in Q2. Article | Follow @EricPFierce

@CarlyHFierce: Sovaldi payer pushback hurting access for opioid treatment patients. Story | Follow @CarlyHFierce

> InterMune takeover talk is tantalizing, but are investors too optimistic? Report

> Merck's sleep drug suvorexant overcomes hurdles to win FDA approval. Article

> The irrational rationale for cancer drug prices, with Novartis' Zykadia as exhibit A. Story

Medical Device News

@FierceMedDev: ICYMI: Here's yesterday's issue of FierceDrugDelivery. | Follow @FierceMedDev

@StacyALawrence: You're so fierce: A call for nominations of the top women in med tech. Editor's corner | Follow @StacyALawrence

@VarunSaxena2: Big VC scoop from my colleague : Sofinnova spinoff HealthQuest targets $110M, makes first investments. News | Follow @VarunSaxena2

@EmilyWFierce: ICYMI yesterday: Medicated electrospun fabric offers alternative delivery method for HIV-preventing drugs. FierceDrugDelivery story | Follow @EmilyWFierce

> J&J freed from Stryker lawsuit, could face renewed battle with Medinol over stent patents. More

> Sofinnova spinoff HealthQuest targets $110M, makes first investments. Story

> California devicemaker rakes in $15M for innovative transcarotid stent system. Article

Vaccines News

> Sanofi's high-dose Fluzone beats standard-dose version in protecting seniors. More

> Researchers retract narcolepsy study linked to Glaxo's Pandemrix. Report

> Health Canada signs off on GSK's plans to improve its flu vaccine plant. More

> Pfizer's Prevnar gets $2B boost with CDC nod in older adults. Article

> Dendreon's debt plans could leave stockholders in the lurch. Story

Pharma Manufacturing News

> Shire takes over production of Buccolam after contractor fails. Article

> Amgen recalls Aranesp syringes contaminated with polyester. Report

> Indian regulator lays down new standards for its inspectors. More

> Baxter recalls another lot of saline solution as shortage persists. Story

> Canada says GSK flu vaccine plant is on track; the FDA remains mum. Item

> Wockhardt's run-ins with the FDA cost it most of its profits for a quarter. Article

Suggested Articles

Nearly two years after raising $75 million, iTeos Therapeutics is picking up $125 million to push its lead assets through phase 1/2 trials.

Bristol Myers Squibb and bluebird bio filed their BCMA-targeting CAR-T therapy for FDA approval, teeing it up for a potential green light in 2020.

With case counts surging and top officials infected, the U.K. is joining the testing for Gilead Sciences' much-hyped antiviral candidate remdesivir.